A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Public ClinicalTrials.gov record NCT06034743. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).
Study identification
- NCT ID
- NCT06034743
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 796 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 22, 2023 (Actual)
- Primary completion
- May 21, 2025 (Actual)
- Completion
- Oct 10, 2025 (Actual)
- Last update posted
- Jul 30, 2026
2023 – 2025
United States locations
- U.S. sites
- 43
- U.S. states
- 24
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Saraland | Alabama | 36571 | — |
| Research Site | Scottsdale | Arizona | 85054 | — |
| Research Site | Sun City West | Arizona | 85375 | — |
| Research Site | Surprise | Arizona | 85374 | — |
| Research Site | Little Rock | Arkansas | 72211 | — |
| Research Site | Fresno | California | 93720 | — |
| Research Site | Lincoln | California | 95648 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Rancho Cucamonga | California | 91730 | — |
| Research Site | Stanford | California | 94304 | — |
| Research Site | New Haven | Connecticut | 06510 | — |
| Research Site | Clearwater | Florida | 33765 | — |
| Research Site | Jacksonville | Florida | 32204 | — |
| Research Site | Port Orange | Florida | 32127 | — |
| Research Site | Atlanta | Georgia | 30344 | — |
| Research Site | Decatur | Georgia | 30033 | — |
| Research Site | Springfield | Illinois | 62702 | — |
| Research Site | Munster | Indiana | 46321 | — |
| Research Site | Lexington | Kentucky | 40503 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Olive Branch | Mississippi | 38654 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | Kansas City | Missouri | 64128 | — |
| Research Site | Kansas City | Missouri | 64151 | — |
| Research Site | Rosedale | New York | 11422 | — |
| Research Site | The Bronx | New York | 10455 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | Toledo | Ohio | 43614 | — |
| Research Site | Grants Pass | Oregon | 97527 | — |
| Research Site | Bethlehem | Pennsylvania | 18017 | — |
| Research Site | Langhorne | Pennsylvania | 19047 | — |
| Research Site | East Providence | Rhode Island | 02914 | — |
| Research Site | Memphis | Tennessee | 38105 | — |
| Research Site | Brownsville | Texas | 78526 | — |
| Research Site | Corpus Christi | Texas | 78404 | — |
| Research Site | Houston | Texas | 77054 | — |
| Research Site | Sugar Land | Texas | 77479 | — |
| Research Site | Manassas | Virginia | 20110 | — |
| Research Site | Suffolk | Virginia | 23435 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
| Research Site | Milwaukee | Wisconsin | 53295 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 220 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06034743, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06034743 live on ClinicalTrials.gov.